Maintain a profit margin of at least 12% in the nutraceuticals-related business
First written in FY2022. 1 of 2 entries say "Advanced", first in FY2023. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AdvancedAnnual report
「In the nutraceuticals-related business, revenue continued to grow steadily while the business profit margin was maintained at 12% or higher. Revenue and business profit both reached record highs for the second consecutive fiscal year.」
The nutraceuticals business maintained a margin of at least 12% for the second consecutive period, with both revenue and business profit reaching record highs. - FY2022First statedAnnual report
「Although revenue from the nutraceuticals business continued to grow steadily, the business maintained a margin of at least 12%, and both revenue and business profit reached record highs for the second consecutive period. The company aims to further expand the scale of the business and improve profitability by establishing its brands in high-growth markets.」
The company specified its intention to maintain a nutraceuticals business margin of at least 12% and improve scale and profitability by establishing its brands in high-growth markets.